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Abstract
Background Alendronate is an inhibitor of osteoclast-me-
diated bone resorption, but its clinical utility is limited due
to gastrointestinal complications including bleeding
erosions.
Aims We studied whether potent vasodilators hydrogen
sulfide (H2S) and carbon monoxide (CO) can protect
against alendronate-induced gastric lesions in rats exposed
to mild stress.
Methods Three series (A, B, and C) of Wistar rats received
alendronate (150–700 mg/kg i.g., series A) with or without
NaHS (5 mg/kg), H2S donor or CORM-2 (5 mg/kg)
releasing CO administered i.g. 30 min before alendronate
administration (series B) in rats exposed for 3 days before
alendronate administration to mild stress (series C). The
area of gastric lesions was assessed by planimetry, the
gastric blood flow (GBF) was determined by H2-gas
clearance technique, and H2S production via CSE/CBS/3-
MST activity and the gastric expression of HO-1, HO-2,
HIF-1a, NF-jB, iNOS, COX-2, IL-1b, TNF-a, GPx-1 and
SOD-2 were analyzed by qPCR or Western blot.
Results Alendronate dose-dependently produced gastric
mucosal lesions and significantly decreased GBF, and these
effects were exacerbated by mild stress. NaHS and CORM-
2 significantly reduced the alendronate-induced gastric
lesions in non-stressed and stressed animals, but only
NaHS but not CORM-2 raised H2S production. NaHS and
CORM-2 inhibited gastric expression of HIF-1a protein
and HO-1, HIF-1a, NF-jB, COX-2, iNOS, IL-1b, TNF-a
mRNAs but failed to affect those of HO-2, GPx-1, and
SOD-2.
Conclusion Both H2S and CO released from their donors,
NaHS and CORM-2, protect gastric mucosa compromised
by stress against alendronate-induced gastric damage via
mechanism involving downregulation of HIF-1a, NF-jB
and proinflammatory factors COX-2, iNOS, IL-1b, and
TNF-a.
Keywords Alendronate  Gastroprotection  Hydrogen
sulfide  Carbon monoxide  Gastric blood flow  Hypoxia-
inducible factor-1a
Introduction
Bisphosphonates (BPs) are chemically non-metabolized
analogs of inorganic pyrophosphate (PPi), where two P–O
bonds were replaced by two C–P structures. This modifi-
cation determines their resistance to chemical and
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enzymatic degradation [1–3]. BPs are among the most
widely and effectively agents used in the therapy of dis-
eases related to bone remodeling, e.g., osteoporosis and
Paget’s disease [4–6]. There are two major classes of BPs-
non-nitrogen-containing BPs (NBP, e.g., etidronic acid and
clodronic acid) [7, 8] and nitrogen-containing BPs (e.g.,
alendronic acid, zoledronic acid, and pamidronic acid)
[9–12]. Different structures of these two classes of BPs
determine their pharmacokinetics and primary mechanism
of action. Previous studies revealed that oral administration
of BPs, such as alendronate, can cause gastrointestinal
adverse effects ranging from mild acid reflux, nausea,
vomiting, and diarrhea to serious complications such as
gastric erosions and even gastric ulcers [13, 14].
Two enzyme systems are involved in the production of
gaseous cellular messenger molecules, carbon monoxide
(CO) and hydrogen sulfide (H2S). The heme oxygenase
(HO) system is composed by microsomal enzymes, which
catalyze a-specific oxidative cleavage of heme to CO,
biliverdin and free iron in a multistep, energy-required
reaction [15]. The HO-1 isoform with widespread tissue
distribution, including the lung, liver, and kidney, has
been shown to be overexpressed by a number of stressors
[16]. Both HO-1 expression and activity have been also
identified in the gastric mucosa [17–19]. Constitutive HO-
2 is expressed at high level in the brain and testes [20].
The endogenous H2S biosynthesis depends upon the
activity of cystathionine-b-synthase (CBS)/cystathionine-
c-lyase (CSE) system, which has been shown to regulate
homocysteine and cysteine metabolism [21, 22]. In
addition, H2S may be synthesized by 3-mercaptopyruvate
sulfotransferase (3-MST) [23]. Interestingly, increased
activity of key H2S enzymatic CSE/CBS pathway seems
to afford gastroprotection against stress-induced ulcero-
genesis [24] and has been shown to promote ulcer healing
in rats [25]. Both H2S and CO were reported to contribute
to a modulation of a variety of physiological processes,
including vasodilatation, neurotransmission, platelet acti-
vation, and aggregation, and have recently emerged as
important signaling molecules in gastrointestinal (GI)
tract [26–29].
Recent studies revealed that H2S released from its
donor, NaHS or synthesized from L-cysteine, exerts gas-
troprotection against non-topical vascular injury induced
by ischemia/reperfusion and topical corrosive irritants such
as ethanol [30, 31]. Our group demonstrated that H2S
affords gastroprotection against gastric bleeding erosions
induced by water immersion and restraint stress (WRS)
[24]. Furthermore, CO administered exogenously or that
generated endogenously due to the enhanced HO-1 activity
has been shown to prevent gastric mucosa against damage
induced by ethanol or nonsteroidal anti-inflammatory drugs
(NSAIDs) such as aspirin [19, 32].
GI tract is one of the most susceptible systems to stressful
stimuli [33]. Local mechanisms for multiple superficial stress-
induced lesions are mucosal ischemia, fall in gastric microcir-
culation, inhibition of gastricmucosal prostaglandins synthesis,
and limited mucosal ability to remove back-diffusing protons
[34–37]. Oral NBP therapy is likely to be at high risk of
developing gastric ulcers, especially in gastric mucosa com-
promised by NSAIDs, but whether mild stress can affect the
complications in gastric mucosa associated with a single BPs
treatment has not been so far examined. It is also unknown
whether H2S and CO contribute to the mechanism of gastro-
protection against those two concomitant deleterious factors,
for instance concomitantly observed in BPs patients who suf-
fered from stress episodes [38].
In this study, we selected mild cold stress, which by itself
does not result in gastric lesions [39] to determine the sus-
ceptibility of gastric mucosa to a subsequent alendronate
treatment, and we compared their synergistic injurious action
in the rat stomach compared to alendronate alone under non-
stressed conditions. Our second goal was to investigate the
mechanism of the potential protective action of H2S released
from NaHS, or CO released from its donor, tricar-
bonyldichlororuthenium (II) dimer (CORM-2) against alen-
dronate ulcerogenesis in gastric mucosa with or without
exposure to mild stress with special reference to the alteration
in blood flow (GBF) and changes in activity of endogenous
H2S and CO biosynthetic enzymatic pathways involved in a
potential protective action of these two gaseous mediators.
At molecular level, we have investigated whether H2S
and CO released from their donors NaHS and CORM-2,
respectively, can modulate hypoxia in gastric mucosa via
regulation of mRNA and protein expression for hypoxia-
inducible factor 1a (HIF-1a), and we examined a potent
anti-inflammatory and anti-oxidative actions of CO and
H2S by determination of gastric mucosal mRNA expres-
sion for heme oxygenase-1 (HO-1), HO-2, and proinflam-
matory factors inducible nitric oxide synthase (iNOS),
cyclooxygenase-2 (COX-2), interleukin-1 b (IL-1b), tumor
necrosis factor-a (TNF-a) and expression of anti-oxidative
enzymes, glutathione peroxidase (GPx)-1, and superoxide
dismutase (SOD)-2. We also determined the relation of
HIF-1a with inflammatory factors by determination of
mRNA expression for nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-jB) in gastric mucosa of
rats pretreated with vehicle or H2S and CO donors.
Materials and Methods
Animals
One hundred and forty male Wistar rats with average
weight 220–300 g were used in this study. Rats were fasted
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for 24 h with free access to drinking water before chemi-
cals and drugs application. The study was approved by the
Institutional Animal Care and Use Committee of Jagiel-
lonian University Medical College in Cracow and run in
accordance with the statements of the Helsinki Declaration
regarding handling of experimental animals.
Experimental Design, Chemicals, and Drugs
Treatment
Three series of animals (A, B, and C) were randomly
selected into experimental groups (6–8 rats each). In series
A, rats were administered with single dose of alendronate
applied i.g. in a doses ranging from 150 mg/kg up to
700 mg/kg (Sigma-Aldrich, Schnelldorf, Germany) accord-
ing to the procedure described previously by Ohashi et al.
[40]. Alendronate was dissolved in saline and adjusted to
pH = 7.0 by adding NaOH (0.1 M) or HCl (0.1 M) [41]. In
series B, rats were pretreated with or without NaHS (5 mg/
kg), H2S donor, or CORM-2 (5 mg/kg) releasing CO
administered i.g. 30 min before alendronate administration
(series B). In series C, rats were initially exposed daily to
mild stress for 3 days in total before alendronate adminis-
tration and two hours later after last exposure to stress, they
received the pretreatment with NaHS and CORM-2 before
subsequent alendronate administration, similarly as animals
in series B. In series C, animals were exposed daily for
3 days in total to mild stress by water immersion and
restraint in cold water at 23 C for 30 min (WRS). This
short time period of WRS by itself does not result in
macroscopic gastric lesions as described previously [39]. At
the day 3, the non-stressed control rats (series B) and
stressed rats (series C) were administered with vehicle
(saline) or alendronate applied i.g. in a single dose of
300 mg/kg, which was established in experiments with
dose-dependent damaging effect of this compound. Alen-
dronate at the dose 300 mg/kg was further considered as
effective dose-inducing gastric damage and employed in
majority of our experimentations. In separate groups of rats
(series B and C), NaHS or CORM-2 was administered i.g. in
a dose of 5 mg/kg each, which has been shown previously to
exert gastroprotective effect against gastric mucosal lesions
induced by various damaging agents [19, 24, 31]. Alen-
dronate, NaHS, and CORM-2 were purchased from Sigma-
Aldrich (Schnelldorf, Germany) and administered i.g. using
orogastric tube as described previously [42].
Determination of Gastric Damage, Examination
of GBF, and Gastric Biopsy Sampling for H2S
Production and Molecular Assessment
Three days after alendronate administration, the animals of
all series A–C were anesthetized with pentobarbital
(60 mg/kg i.p.), the abdomen was opened, and the stomach
was exposed to measure GBF by H2-gas clearance tech-
nique as described previously [43]. The GBF was measured
in the oxyntic part of the gastric mucosa not involving
mucosal lesions. Average values of three measurements
were determined and expressed as a percentage of the
change of the GBF value obtained in intact gastric mucosa.
The area of gastric lesions was determined with com-
puterized planimetry (Morphomat, Carl Zeiss, Berlin,
Germany) by a person who did not know which experi-
mental group the animals belonged to [19, 43]. Gastric
mucosal biopsies (about 200 mg) were taken for the
determination of H2S biosynthesis, and the remaining part
of stomach was scrapped off on ice, snap-frozen in liquid
nitrogen, and stored at-80 C for further analysis.
Determination of H2S Production Via CSE/CBS
and 3-MST Pathways in Gastric Mucosa
The ability of gastric mucosa to produce H2S via CSE/CBS
or 3-MST pathway was measured in homogenized tissue in
the presence of exogenous substrates using previously
described zinc (Zn)-trapping assay [24, 44]. Briefly, gastric
mucosa was quickly isolated from uninjured sites, snap-
frozen, and stored at -80 C. The gastric tissue was
homogenized in ice-cold 50 mM potassium phosphate
buffer, pH = 8.0 (12 % w/v). L-cysteine (10 mM) and
pyridoxal-50-phosphate (P5P) or a-ketoglutarate (a-KG)
was added to the tissue homogenate, and the vials includ-
ing inner tubes with Zn acetate were then incubated in a
shaking water bath at 37 C for 90 min. Trichloroacetic
acid (TCA; 50 %; 0.5 ml) was then injected into the
reaction mixture through the serum cap. The mixture was
left to stand for another 60 min in 50 C to allow for the
trapping of evolved H2S by the Zn acetate. N,N-dimethyl-
p-phenylenediamine sulfate (20 mM; 50 ll) in 7.2 M HCl
and FeCl3 (30 mM; 50 ll) in 1.2 M HCl were added to the
inner tubes. After 20 min, absorbance at 670 nm was
measured with a microplate reader (Tecan Sunrise, Män-
nedorf, Switzerland). The calibration curve of absorbance
vs. H2S concentration was obtained by using NaHS solu-
tion of varying concentrations.
Determination of mRNA Expression for HO-1, HO-
2, HIF-1a, NF-jB, COX-2, iNOS, TNF-a, IL-1b,
SOD-2, and GPx-1 in Rat Gastric Mucosa by Real-
Time Polymerase Chain Reaction (qPCR)
Expression of mRNA in gastric mucosa was determined by
real-time PCR as described previously [19]. Briefly, RNA
was isolated from gastric mucosal biopsies stored at
-80 C using GeneMATRIX Universal RNA Purification
Kit (EURx, Gdansk, Poland) and reversed transcription to
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cDNA was performed using High-Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientific, Life Tech-
nologies, MA, USA). Expression for HO-1, HO-2, HIF-1a,
NF-jB, COX-2, iNOS, TNF-a, IL-1b, SOD-2, and GPx-1
was determined by real-time PCR using specific primers,
SG qPCR Master Mix (2x) including SYBR-Green (EURx,
Gdansk, Poland) and appropriate thermal cycler (7900HT
Fast Real-Time PCR System, Thermo Fisher Scientific,
Life Technologies, MA, USA). The nucleotide sequences
of the primers used in PCR are presented in Table 1. The
b-actin gene was used as an internal control. Data were
analyzed using 2-DCt method [45].
Protein Expression of HIF-1a in Gastric Mucosa
Determined by Western Blot
Western blot analysis was used to determine gastric
expression of HIF-1a in gastric mucosal samples as
described previously [19]. Rabbit polyclonal anti-HIF-1a
(Proteintech, Manchester, UK) in dilution of 1:250 in 5 %
milk (incubation in 4 C, overnight) and rabbit policlonal
anti-b-actin (Proteintech) in dilution of 1:2000 in 5 % milk
(incubation in room temperature, 3 h) were used as primary
antibodies. Protein expression was visualized using a
horseradish peroxidase-conjugated secondary goat anti-
rabbit IgG antibodies (Santa Cruz Biotechnology, Texas,
USA) in dilution of 1:2000 in 5 % milk (incubation time
1 h, room temperature). Chemiluminescence was measured
using C-DiGit Blot Scanner (LI-COR, NE, USA). The
intensity of the bands was determined and analyzed using
Image Studio 4.0 software (LI-COR, NE, USA). The
expression of each sample was normalized to the expres-
sion of b-actin protein.
Statistical Analysis
Results are expressed as mean ± SEM. Statistical com-
parison was made by Mann–Whitney U test or Student’s
T test. ANOVA with Tukey post hoc or Kruskal–Wallis
with Dunn’s post hoc test was used where appropriate.
Difference with p\ 0.05 was considered significant.
Results
Figure 1 shows that pretreatment with alendronate
(150–700 mg/kg i.g.) dose-dependently increased the mean
area of gastric lesions and significantly decreased GBF
(p\ 0.05). The lower doses 37.5 mg/kg or 75 mg/kg of
alendronate failed to induce the gross mucosal lesions, and
these results were omitted from the presentation. With
increasing the dose of alendronate up to 150 mg/kg, the
gastric mucosal lesions were detected and the GBF was
significantly decreased (p\ 0.05) compared with vehicle
(saline) control rats (Fig. 1). The mean area of these gastric
Table 1 Forward and reverse
primers used in the assessment
of mRNA expression for b-
actin, HO-1, HO-2, HIF-1a,
COX-2, iNOS, TNF-a, IL-1b,
SOD-2, and GPx-1 by real-time
PCR
Gene Forward primer Reverse primer
b-actin 50-GATCAAGATCATTGCTCCTCCTG-30 50-AGGGTGTAAAACGCAGCTCA-30
HO-1 50-GTCCCAGGATTTGTCCGAGG-30 50-GGAGGCCATCACCAGCTTAAA-30
HO-2 50-CCGGGCAGAAAATACCCAGT-30 50-ATCAGTGCTTCCTTCCGGTG-30
HIF-1a 50-ATCCATTTTCAGCTCAGGACAC-30 50-GGTAGGTTTCTGTAACTGGGTCTG-30
NF-jB 50-TTCAACATGGCAGACGACGA-30 50-CCATCTGTTGACAGTGGTATATCTG-30
COX-2 50-ATCAGAACCGCATTGCCTCT-30 50-GCCAGCAATCTGTCTGGTGA-30
I NOS 50-TGGTGAGGGGACTGGACTTT-30 50-CTCCGTGGGGCTTGTAGTTG-30
IL-1b 50-GCTATGGCAACTGTCCCTGA-30 50-AGTCAAGGGCTTGGAAGCAA-30
TNF-a 50-TGGGCTCCCTCTCATCAGTT-30 50-TCCGCTTGGTGGTTTGCTAC-30
SOD-2 50-GTGGAGAACCCAAAGGAGAGT-30 50-GGTCCTGATTAGAGCAGGCG-30
GPx-1 50-CATTGAGAATGTCGCGTCCC-30 50-TTGCCATTCTCCTGATGTCCG-30
Fig. 1 Mean lesion area and gastric blood flow (GBF) level in gastric
mucosa after alendronate administration (150–700 mg/kg i.g.).
Results are mean ± SEM of 6–8 animals for each experimental
group. Single asterisk indicates a significant change (p\ 0.05) as
compared with vehicle (saline). Asterisk and cross indicate a
significant change (p\ 0.05) as compared with vehicle-control rats
and with the group with alendronate administered i.g. in the dose of
150 mg/kg
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lesions was further significantly increased (p\ 0.05), and
GBF level was significantly decreased (p\ 0.05) when
alendronate was administered in the dose of 300 mg/kg i.g.
as compared with the lower dose of 150 mg/kg of alen-
dronate. Intragastric administration of alendronate in
higher dosages of 500 and 700 mg/kg significantly
increased the mean lesions area (p\ 0.05) and produced a
significant fall in GBF as compared with the values
observed in animals treated with the dose of 150 mg/kg
(p\ 0.05) but failed to show significant difference as
compared with the dose of 300 mg/kg i.g. Therefore, the
dose of 300 mg/kg i.g. of alendronate was selected in
further experiments and considered as the truly effective
and reproducible dose-inducing gastric damage.
As shown in Fig. 2, the pretreatment with CORM-2 or
NaHS administered in the dose of 5 mg/kg i.g. each, which
was shown in our previous studies to reduce gastric lesions
by stress and ethanol [19, 24, 31], significantly decreased
alendronate-induced increase in mean lesion area
(p\ 0.05) and significantly increased GBF as compared
with vehicle-control rats (p\ 0.05). Preexposure of rats for
3 days with mild stress significantly increased alendronate-
induced gastric damage (p\ 0.05) and significantly
decreased the GBF (p\ 0.05) as compared with those in
vehicle-treated animals. NaHS and CORM-2 administered
in the dose of 5 mg/kg significantly decreased the mean
lesion area of alendronate-treated rats (p\ 0.05) and sig-
nificantly increased the GBF in gastric mucosa of non-
stressed and stressed animals treated with this agent as
compared with respective values in vehicle controls
(p\ 0.05).
The macroscopic appearance of rats gastric mucosa
pretreated with alendronate (300 mg/kg i.g.) with or
without preexposure to mild WRS is presented in Fig. 3a,
b, respectively. Alendronate-induced superficial gastric
damage, observed as a gray necrotic layer of desquamated
epithelium, predominantly located in antral part of gastric
mucosa (Fig. 3a). In rats preexposed to mild WRS, alen-
dronate caused numerous gastric hemorrhagic dot-like
erosions and band-like lesions which were observed in
oxyntic part of the stomach in spite of necrotic damage
caused by this agent in antrum (Fig. 3b). Figure 3 (panels
C and D) shows the representative gross gastric mucosal
injury induced by alendronate in rats compromised by mild
WRS and pretreated with CORM-2 (5 mg/kg i.g., Fig. 3c)
or NaHS (5 mg/kg i.g., Figure 3d). CORM-2 and NaHS
had evidently reduced gross mucosal lesions in rats pre-
exposed to mild WRS followed by administration of
alendronate (Fig. 3b, c, d).
Production of H2S in gastric mucosa assessed by activity
of CSE/CBS was not significantly affected by mild WRS
alone as compared to intact rats (Fig. 4a). In rats treated
with alendronate (300 mg/kg i.g.) and previously exposed
or not to mild WRS, the H2S production analyzed by CSE/
Fig. 2 Mean lesion area of gastric lesions induced by alendronate
(300 mg/kg i.g.) and accompanying changes in the gastric blood flow
(GBF) in gastric mucosa administered with NaHS (5 mg/kg i.g.) or
CORM-2 (5 mg/kg i.g.) with or without exposure to mild stress
(WRS). Results are mean ± SEM of 6–8 animals for each experi-
mental group. Asterisk or cross indicate significant change (p\ 0.05)
as compared with non-stressed vehicle control. Asterisk and cross
indicate significant (p\ 0.05) difference as compared with vehicle-
control gastric mucosa compromised by mild WRS
Fig. 3 a–d The representative appearance of alendronate-induced
gastric lesions in the rat stomach compromised or not with mild water
immersion and restraint stress (WRS) with or without i.g. pretreat-
ment with CORM-2 (5 mg/kg) or NaHS (5 mg/kg). Note, the
presence of superficial gastric lesions mainly localized in antral part
of gastric mucosa in rat stomach exposed to alendronate (300 mg/kg
i.g.) (a). In gastric mucosa compromised by mild WRS and
administered with alendronate (300 mg/kg i.g.) additionally to
damage in antrum, the numerous dot-like and band-like lesions are
visible in oxyntic mucosa (b). In rats pretreated with CORM-2 (c) or
NaHS (d), the total area of alendronate-induced gastric lesions
compromised by mild WRS is markedly reduced (b, c, d)
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CBS pathway was significantly decreased (p\ 0.05) as
compared with intact rats. The pretreatment with NaHS but
not CORM-2 significantly increased (p\ 0.05) the gastric
mucosal production of H2S determined by CSE/CBS
activity as compared with that in gastric mucosa of rats
compromised by mild WRS and subsequently treated with
the combination of vehicle and alendronate (Fig. 4a).
Similarly, H2S production assessed via 3-MST activity was
significantly decreased either in non-stressed or in stressed
animals and administered with alendronate (300 mg/kg
i.g.) (p\ 0.05) as compared with intact animals (Fig. 4b).
Again, pretreatment with NaHS but not CORM-2 reversed
this effect significantly increasing H2S production by
3-MST as compared with vehicle-control gastric mucosa
compromised by mild WRS and administered with alen-
dronate (p\ 0.05) (Fig. 4b).
Figure 5 (panels A and B) shows mRNA expression of
HO-1 (panel A) and HO-2 (panel B) in intact gastric
mucosa and in that pretreated with vehicle, NaHS or
CORM-2 in rats compromised by mild WRS with or
without alendronate treatment. Alendronate administered
alone significantly increased mRNA expression for HO-1
as compared with intact rats (p\ 0.05) while mild WRS
remained without significant effect. Preexposure of gastric
mucosa to mild WRS significantly increased alendronate-
induced upregulation of HO-1 mRNA expression
(p\ 0.05). NaHS (5 mg/kg i.g.) and CORM-2 (5 mg/kg
i.g.) significantly decreased HO-1 mRNA expression as
compared with vehicle-control gastric mucosa in rats
compromised by mild WRS for 3 days before the admin-
istration of alendronate (p\ 0.05) (Fig. 5a). As shown in
Fig. 5b, mild WRS and alendronate significantly decreased
mRNA expression for HO-2 (p\ 0.05), and this effect was
not significantly altered when mild WRS was combined
with alendronate as compared with animals preexposed to
mild WRS alone or administered with alendronate. Neither
CORM-2 nor NaHS had influenced the downregulation of
HO-2 mRNA expression induced by the combination of
alendronate and mild WRS (Fig. 5b).
Expression of mRNA and protein for HIF-1a in gastric
mucosa is presented in Fig. 6a, b, respectively. Both mild
WRS and alendronate failed to affect mRNA and protein
expression of HIF-1a, but when alendronate was combined
with mild WRS, a significant increase in gastric mRNA and
protein expression of HIF-1a was observed as compared
with intact rats and those preexposed to mild WRS only or
administered with alendronate alone (p\ 0.05). The pre-
treatment with CORM-2 (5 mg/kg i.g.) or NaHS (5 mg/kg
i.g.) significantly decreased the mRNA and protein
expression of HIF-1a as compared with vehicle-control
gastric mucosa compromised by mild WRS and adminis-
tered with alendronate (p\ 0.05).
Figure 7 shows the effect of alendronate with or without
the pretreatment with NaHS or CORM-2 on mRNA
expression of NF-jB in non-stressed rats and those pre-
exposed to mild WRS. Alendronate combined with mild
WRS significantly increased mRNA expression for NF-jB
as compared with intact gastric mucosa (p\ 0.05) (Fig. 7).
CORM-2 (5 mg/kg i.g.) or NaHS (5 mg/kg i.g.) signifi-
cantly decreased the mRNA expression of NF-jB as
compared with vehicle-control gastric mucosa compro-
mised by mild WRS and administered with alendronate
(p\ 0.05) (Fig. 7).
Figure 8 (panels A and B) shows mRNA expression for
iNOS (panel A) and COX-2 (panel B) in non-stressed rats
and those preexposed to mild WRS and treated with
alendronate. When alendronate was combined or not with
mild WRS, mRNA expression for iNOS was significantly
increased, as compared with intact gastric mucosa
Fig. 4 a, b The effect of mild WRS and alendronate (300 mg/kg i.g.)
alone and the combination of mild WRS and alendronate (300 mg/kg
i.g.) with or without pretreatment with CORM-2 (5 mg/kg i.g.) or
NaHS (5 mg/kg i.g.) on H2S production in gastric mucosa determined
by CSE/CBS (a) or 3-MST (b) activity in gastric mucosa. Results are
mean ± SEM of 4–6 rats per each group. Significant change
(p\ 0.05) as compared with the respective values in intact rats was
indicated by asterisk. Cross indicates significant change (p\ 0.05)
comparing to the values obtained in vehicle-control gastric mucosa
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(p\ 0.05) (Fig. 8a). The expression of COX-2 mRNA was
significantly increased in gastric mucosa compromised by
mild WRS and administered with alendronate comparing to
that in intact gastric mucosa (p\ 0.05) (Fig. 8b). CORM-2
(5 mg/kg i.g.) or NaHS (5 mg/kg i.g.) significantly
decreased mRNA expression of iNOS and COX-2 as
compared with vehicle-control gastric mucosa of rats
compromised by mild WRS and administered with alen-
dronate (p\ 0.05) (Fig. 8a, b).
Figure 9 (panels A and B) presents data on mRNA
expression for IL-1b (panel A) and TNF-a (panel B) in
non-stressed and stressed rats treated with alendronate. The
significant increase in mRNA expression for IL-1b and
TNF-a was observed in gastric mucosa of rats exposed to
mild WRS (vehicle-control) and treated with alendronate
as compared with intact gastric mucosa (p\ 0.05)
(Fig. 9a, b). The pretreatment with CORM-2 (5 mg/kg i.g.)
or NaHS (5 mg/kg i.g.) significantly decreased gastric
mucosal mRNA expression of these cytokines as compared
with vehicle controls (p\ 0.05).
As shown in Fig. 10 (panels A and B), the mRNA
expression for GPx-1 and SOD-2 was significantly
decreased in alendronate-treated rats preexposed to mild
WRS as compared with that recorded in intact gastric
mucosa (p\ 0.05). The expression of GPx (panel A) and
SOD-2 (panel B) mRNAs was significantly decreased in
gastric mucosa compromised by mild WRS and further
pretreated with vehicle (control) and administered with
alendronate as compared with intact rats (p\ 0.05). The
pretreatment with NaHS (5 mg/kg i.g.) and CORM-2
(5 mg/kg i.g.) did not affect mRNA expression for GPx and
SOD-2 downregulated in vehicle-control group of rats
exposed to the combination of mild WRS and alendronate
(panels A and B).
Discussion
The resistance of stomach to gastric mucosal injury is
maintained by the mucosal defense mechanisms consisting
of protective mucus and alkaline secretion of bicarbonate,
the maintenance of gastric microcirculation, the
hydrophobicity of mucosal surface, the presence of
vasoactive agents such as prostaglandins (PGs), sensory
neuropeptides released from primary afferent capsaicin-
sensitive sensory neurons, and three interacting gaseous
mediators NO, CO, and H2S [28, 31, 46–48].
The use of BPs has been reported to be closely associ-
ated with GI adverse events in humans and experimental
animals [49]. In our study, we adapted experimental model
of alendronate-induced gastric damage [40], and we con-
firmed that this drug when administered orally in graded
concentrations caused macroscopic lesions in the rat
stomach. Our results are corroborative with previous
observations that various BPs evoke mainly antral lesions
accompanied by severe edema, neutrophil accumulation,
and epithelial cell loss determined microscopically
[50–52].
It has been recognized long time ago that the gastric
microcirculation plays a crucial role in gastric mucosal
defense [53], and this study provides the evidence that
alendronate-induced gastric damage is accompanied by the
Fig. 5 a, b Expression of mRNA for HO-1 (a) and HO-2 (b) in
gastric mucosa of intact rats or those exposed to mild water
immersion and restraint stress (WRS) alone or administered with
alendronate (300 mg/kg i.g.) alone or in combination with mild WRS
with or without pretreatment with CORM-2 (5 mg/kg i.g.) or NaHS
(5 mg/kg i.g.). Results are expressed as the HO-1 and HO-2 mRNA
expression normalized to b-actin. Results are mean ± SEM of
6–9 determinations per group. Asterisk indicates a significant change
(p\ 0.05) as compared with the respective values in intact gastric
mucosa. Double asterisk indicates significant change (p\ 0.05) as
compared with intact rats and those administered with alendronate
(300 mg/kg i.g.) alone. Cross indicates a significant change
(p\ 0.05) comparing to values obtained in vehicle-control group
compromised by mild WRS and treated with alendronate
3182 Dig Dis Sci (2016) 61:3176–3189
123
decrease in GBF. The prominent fall in GBF was observed
with the dose of 300 mg/kg of alendronate, which was
further used in our subsequent determinations. Thus, we
demonstrated that the formation of gastric damage by
alendronate is associated with perturbation in the GBF,
which could be at variance with previous observations [54].
This discrepancy reflecting alteration in GBF may be due
to different dosages of BPs and techniques of assessment of
gastric mucosal blood flow used before [54] and in our
present study. In the present study, we demonstrated for the
first time that preexposure of rats to mild stress exacerbated
the alendronate-induced gastric damage and produced
greater fall in GBF as compared with those recorded in
non-stressed animals exposed to alendronate. Therefore,
we propose that this mild stress could weaken the gastric
mucosal barrier, thus predisposing gastric mucosa to injury
induced by alendronate. Interestingly, the increased sus-
ceptibility for gastric damage induced by BPs has been
previously observed in rats pretreated with indomethacin
[38].
Hypoxia-inducible factor 1 alpha (HIF-1a), the tran-
scription factor, whose expression is oxygen-dependent
and increased by prolonged hypoxia, has been shown to
contribute to tumor proliferation and angiogenesis [55–57].
In our present study, the alendronate-induced gastric
damage in rats preexposed to mild stress resulted in an
increase in mRNA and protein expression for HIF-1a; the
effect that has not been observed in non-stressed rats
administered with alendronate. Thus, we propose that the
mechanism of mild stress affecting pathomechanism of
Fig. 6 a, b Expression of mRNA and protein for HIF-1a in gastric
mucosa of intact rats or those exposed to mild water immersion and
restraint stress (WRS) alone or administered with alendronate
(300 mg/kg i.g.) alone or those exposed to the combination of mild
WRS and alendronate (300 mg/kg i.g.) with or without pretreatment
with CORM-2 (5 mg/kg i.g.) or NaHS (5 mg/kg i.g.). Results are
expressed as the HIF-1a mRNA or protein expression of HIF-1a
normalized to b-actin. Results are mean ± SEM of 4–8 determina-
tions per group. Asterisk indicates a significant change (p\ 0.05) as
compared with the respective values in intact gastric mucosa. Cross
indicates a significant change (p\ 0.05) as compared with the values
obtained in vehicle-control gastric mucosa compromised by mild
WRS and administered with alendronate (300 mg/kg i.g.). Represen-
tative protein expression bands for each experimental group are
presented at the bottom of (b)
Fig. 7 Expression of mRNA for NF-jB in gastric mucosa of intact
rats or those exposed to mild water immersion and restraint stress
(WRS) alone or administered with alendronate (300 mg/kg i.g.) alone
or those exposed to the combination of mild WRS and alendronate
(300 mg/kg i.g.) with or without pretreatment with CORM-2 (5 mg/
kg i.g.) or NaHS (5 mg/kg i.g.). Results are expressed as the NF-jB
mRNA expression normalized to b-actin. Results are mean ± SEM of
4-8 determinations per group. Asterisk indicates a significant change
(p\ 0.05) as compared with the respective values in intact gastric
mucosa. Cross indicates a significant change (p\ 0.05) as compared
with the values obtained in vehicle-control gastric mucosa compro-
mised by mild WRS and administered with alendronate (300 mg/kg
i.g.)
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alendronate-induced gastric damage may involve hypoxia,
which can trigger exacerbation of alendronate-induced
ulcerogenesis in the rat stomach. This notion is supported
by our finding that expression of NF-jB mRNA as well as
HIF-1a was increased in gastric mucosa compromised by
mild stress and administered with alendronate. These
observations suggest that NF-jB pathway plays a role in
injurious action of alendronate due to regulation of
hypoxia, which remains corroborative with the conclusion
of study by van Uden et al. [58] who demonstrated in vitro
that NF-jB is involved in the regulation of HIF-1a
expression. Moreover, we observed that expression of
mRNA expression for HO-1, possibly enhanced by
inflammation and pro-inflammatory factors iNOS, COX-2,
and cytokines such as IL-1b and TNF-a, was increased in
gastric mucosa compromised by mild stress and adminis-
tered with alendronate. Additionally, the mRNA expression
of anti-oxidative enzymes GPx-1 and SOD-2 was inhibited
in alendronate-treated animals with or without preexposure
to mild stress. This indicates that mild stress not only
exacerbated the alendronate-induced gastric damage pos-
sibly mediated by the enhanced expression of pro-
Fig. 8 a, b Expression of mRNA for iNOS (a) and COX-2 (b) in
gastric mucosa of intact rats or those exposed to mild water
immersion and restraint stress (WRS) alone or administered with
alendronate (300 mg/kg i.g.) alone or those exposed to the combi-
nation of mild WRS and alendronate (300 mg/kg i.g.) with or without
pretreatment with CORM-2 (5 mg/kg i.g.) or NaHS (5 mg/kg i.g.).
Results are expressed as the iNOS and COX-2 mRNA expression
normalized to b-actin. Results are mean ± SEM of 4-8 determina-
tions per group. Asterisk indicates a significant change (p\ 0.05) as
compared with the respective values in intact gastric mucosa. Cross
indicates significant change (p\ 0.05) as compared with the values
obtained vehicle-control gastric mucosa compromised by mild WRS
and administered with alendronate (300 mg/kg i.g.)
Fig. 9 a, b The expression of mRNA for TNF-a (a) and IL-1b (b) in
gastric mucosa of intact rats or those exposed to mild water
immersion and restraint stress (WRS) alone or those exposed to the
combination of mild WRS and alendronate (300 mg/kg i.g.) with or
without pretreatment with CORM-2 (5 mg/kg i.g.) or NaHS (5 mg/kg
i.g.). Results are expressed as the TNF-a and IL-1bmRNA expression
normalized to b-actin. Results are mean ± SEM of 4–8 determina-
tions per group. Asterisk indicates a significant change (p\ 0.05) as
compared with the respective values in intact gastric mucosa. Cross
indicates significant change (p\ 0.05) as compared with the values
obtained vehicle-control gastric mucosa compromised by mild WRS
and administered with alendronate (300 mg/kg i.g.)
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inflammatory factors but also profoundly decreased
expression of anti-oxidative enzymes GPx-1 and SOD-2.
This observation is in keeping with the findings by Nicolau
et al. [41] and Silva et al. [59] who also reported increased
TNF-a and IL-1b protein concentration in alendronate-
treated gastric mucosa. However, in contrast to our findings
where a single dose of alendronate was used in majority of
our experiments, Silva et al. [59] have demonstrated
decreased iNOS and eNOS protein expression after 4 days
of subsequent alendronate administrations, suggesting that
suppression of major enzymes of NO biosynthesis could be
considered as one of the possible mechanism by which this
drug evokes its damaging activity. This effect on NO
biosynthesis caused by chronic vs single alendronate
administration should be further determined but our
experimental design with alendronate administered in a
large single dose resulted in an excessive production of NO
possibly derived from overexpression of iNOS acting as a
potentially harmful agent and the proinflammatory factor in
the gastric mucosa [60–62]. Nevertheless, the decreased
gastric mucosal glutathione (GSH) and the increased
malondialdehyde (MDA) contents reported in their study
[59] and diminished GPx-1 and SOD-2 mRNA expression
demonstrated in our present work clearly indicate that
alendronate-evoked gastric lesions are due to a failure of
anti-oxidative mechanisms in gastric mucosa exposed to
this BPs.
Interestingly, we demonstrated to our best knowledge
for the first time that H2S production via CSE/CBS and
3-MST pathways was markedly decreased in gastric
mucosa compromised by mild WRS and administered with
alendronate, suggesting that this gaseous mediator pro-
duced endogenously plays a crucial role in pathogenesis of
alendronate-induced gastric lesions. This notion is
supported by the fact that the activity of these H2S-keynote
enzymes was decreased in vehicle-pretreated control rats
administered with alendronate and exposed or not to mild
WRS. This effect was accompanied by the decreased
mRNA expression for HO-2, which is one of two major
enzymes, besides HO-1, producing endogenous CO. We
conclude that CO next to H2S can be involved in patho-
genesis of damage induced by alendronate and could be
also implicated in gastroprotection against alendronate-in-
duced damage of gastric mucosa compromised or not by
mild stress.
We found that H2S donor, NaHS, and CO-releasing
CORM-2 attenuated gastric mucosal lesions induced by
alendronate and that this effect was accompanied by the
rise in GBF. Moreover, the preexposure of gastric mucosa
to mild stress exaggerated alendronate-induced gastric
damage, and the pretreatment with NaHS and CORM-2
also reduced these lesions and elevated GBF. These find-
ings confirm our previous observations that CORM-2
(1 mg/kg i.g.) and NaHS (5 mg/kg i.g.) prevented gastric
mucosa against stress-induced gastric damage [24, 63]. In
this study, both compounds were administered in the dose
of 5 mg/kg i.g., which has been shown in our previous
studies to exert gastroprotection against acute WRS- and
ethanol-induced gastric damage [19, 24, 31]. Interestingly,
at the dose used in our present study, CORM-2 has been
shown to increase CO content in gastric mucosa and COHb
level in blood [19]. Results of our study with both donors
of H2S and CO seem to correspond with the observations of
Costa et al. [51] and Nicolau et al. [41] who showed in two
independent studies that the treatment with dimanganese
decacarbonyl (DMDC) and Lawesson’s reagent, another
compounds donating of CO and H2S, respectively, exhib-
ited a protective effect against alendronate-induced gastric
Fig. 10 a, b The expression of mRNA for GPx-1 and SOD-2 in
gastric mucosa of intact rats or those exposed to mild water
immersion and restraint stress (WRS) alone or administered with
alendronate (300 mg/kg i.g.) alone or those exposed to the combi-
nation of mild WRS and alendronate (300 mg/kg i.g.) with or without
pretreatment with CORM-2 (5 mg/kg i.g.) or NaHS (5 mg/kg i.g.).
Results are expressed as the GPx-1 and SOD-2 mRNA expression
normalized to b-actin. Results are mean ± SEM of 4-8 determina-
tions per group. Asterisk indicates a significant change (p\ 0.05) as
compared with the respective values in intact gastric mucosa
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lesions in rats. Moreover, our present study demonstrates
that NaHS increased H2S production via CSE/CBS and
3-MST activity pathways, which was profoundly decreased
in gastric mucosa compromised by mild stress and
administered with alendronate. This is in keeping with our
previous observation that NaHS increased H2S production
via CSE/CBS activity [24] confirming the ‘‘reciprocal’’
interaction of this chemical donor releasing H2S with
endogenous biosynthesis of this gaseous molecule endorsing
its protective and hyperemic activity against gastric mucosal
injury. Therefore, we conclude that the common mechanism
of protective action of CORM-2 and NaHS against BPs and
other damaging agents can involve an increase in CO and
H2S bioavailability in gastric mucosa.
It is of interest that both CORM-2 and NaHS downreg-
ulated expression of HIF-1amRNA and protein, which were
elevated in gastric mucosa after exposure of rats to com-
bined action of mild stress and alendronate. This confirms
that NaHS-releasing H2S and CORM-2-releasing CO can
afford gastroprotective effects by counteracting of hypoxia,
which is involved in injurious activity and mucosal dys-
function induced by combination of mild stress and alen-
dronate. Indeed, Guillen et al. [64] have demonstrated that
CORM-2 dose-dependently inhibited HIF-1a activation in
primary chondrocytes, and Flannigan et al. [65] have
observed that the H2S-releasing diallyl disulfide while
maintaining the HIF-1a expression reduced the severity of
experimental colitis in rodents. The level of tissue oxygen
seems to be critical because in another study [66] the
administration of H2S inhibited HIF-1a stabilization under
conditions of hypoxia provided by the 1 and 3 % O2 but not
by the level of hypoxia resulting from the 0.1 % O2 content.
We observed that CO and H2S released from their
donors, CORM-2, and NaHS, respectively, clearly reduced
mRNA expression for HO-1. We propose that HIF-1a and
HO-1 expression could act as markers of tissue hypoxia
and inflammation because both HIF-1a and HO-1 mRNAs
expression were increased in gastric mucosa of rats treated
with alendronate and exposed to mild stress. This notion is
supported by the fact that application of CORM-2 or
NaHS, which have decreased HIF-1a stabilization and HO-
1 mRNA expression, greatly reduced hypoxia and inflam-
mation induced by alendronate in gastric mucosa com-
promised by mild stress. Therefore, it is reasonable to
assume that the decrease in stabilization of HIF-1a and the
restoration of HO-1 expression could, at least in part,
account for the observed anti-inflammatory and anti-oxi-
dizing effects of H2S and CO released from NaHS or
CORM-2, respectively.
We observed that CORM-2 and NaHS reduced the
mRNA expression for pro-inflammatory factors including
iNOS, COX-2, and cytokines such as TNF-a and IL-1b that
were all upregulated in gastric mucosa of rats exposed to
the combination of mild stress and alendronate. This is in
parallel with the results of Nicolau et al. [41] who reported
decreased TNF-a and IL-1b levels in alendronate-treated
gastric mucosa after H2S donor administration and the
study of Costa et al. [51] who revealed the same effect after
application of DMDC, a CO donor. Interestingly, CORM-2
and NaHS decreased mRNA expression of NF-jB upreg-
ulated in gastric mucosa compromised by mild stress and
administered with alendronate. This indicates that H2S and
CO can downregulate the NF-jB pathway, thus explaining
in part the anti-hypoxic and anti-inflammatory action of
these gaseous molecules. In agreement with this notion,
Wei et al. [67] have demonstrated that CORM-2 decreased
NF-jB activity and TNF-a concentration in rats with
ischemia-/reperfusion-induced hepatic injury. Moreover,
Chen et al. [68] have shown that NaHS inhibited nuclear
translocation of NF-jB and attenuated TNF-a/interferon-
c-induced injury in monolayer culture of Caco-2 cells.
Interestingly, neither CORM-2 nor NaHS affected
mRNA expression for GPx-1 or SOD-2, which was
downregulated in gastric mucosa compromised by mild
WRS and administered with alendronate. This suggests that
H2S- and CO-induced gastroprotection against mucosal
damage induced by alendronate does not involve the
alterations in expression of these enzymes. However,
Nicolau et al. [41] and Costa et al. [51] have demonstrated
that using different H2S donor, Lawesson’s reagent, and
CO-releasing molecule, DMDC, these donors reversed the
effect of alendronate on the activity of another oxidative
parameters including GSH and MDA in gastric mucosa.
We conclude that endogenous gaseous mediators, CO
and H2S, play an important role in the maintenance of
gastric integrity and exert a beneficial protective effect
against alendronate-induced gastric lesions in the presence
of mild stressor. We provided the evidence that the
increased bioavailability of these gaseous transmitters
released from their donors NaHS and CORM-2 can be
responsible for the gastroprotection against alendronate-
induced gastric damage with or without exposure to mild
stress. Interestingly, the NaHS-induced protection is
accompanied by the increase in endogenous H2S biosyn-
thesis, but CORM-2 seems to act independently from
endogenous H2S. The common mechanism of CO and H2S
gastroprotective action involves an increase in gastric
microcirculation, the reduction in hypoxia by attenuation
of HIF-1a, and the attenuation of inflammation by down-
regulation of NF-jB and pro-inflammatory factors, such as
iNOS, COX-2, IL-1b, and TNF-a expression in gastric
mucosa exposed to alendronate combined with mild stress.
Moreover, our study documented that NaHS and CORM-2
increased the gastric bioavailability of two important
vasoactive mediators H2S and CO, thus contributing to the
restoration of gastric blood flow, which was decreased after
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alendronate administration. Therefore, this local hyperemic
activity of gaseous mediators H2S and CO seems to be
primary mechanism by which these two gaseous mediators
exhibit gastroprotection. This increase in gastric microcir-
culation can contribute to limiting of the extent of hypoxia
and inflammation induced by this bisphosphonate as
manifested in our present study by the decrease in HIF-1a
stabilization and the downregulation of expression of
‘‘cytoprotective’’ HO-1.
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